VIMOVO 375/20 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
107若年性特発性関節炎1

107. 若年性特発性関節炎


臨床試験数 : 447 薬物数 : 297 - (DrugBank : 57) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 146
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01544114
(ClinicalTrials.gov)
April 201221/2/2012A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)Juvenile Idiopathic Arthritis (JIA)Drug: VIMOVO 250/20;Drug: VIMOVO 375/20;Drug: VIMOVO 500/20Horizon Pharma Ireland, Ltd., Dublin IrelandNULLCompleted12 Years16 YearsAll46Phase 4United States